Status | Study |
Active, not recruiting |
Study Name: Evidence Based Patient Information and Smartphone Accelerometry to Enhance Physical Activity in MS Condition: Multiple Sclerosis, Chronic Progressive Date: 2017-03-31 Interventions: Behavioral: Smartphone App The app includes an EBPI and physical activity feedback |
Recruiting |
Study Name: A LOW-COST VIRTUAL REALITY GAMING PLATFORM FOR NEUROREHABILITATION OF HEMIPARESIS Condition: Primary Progressive Multiple Sclerosis Hemiparesis Date: 2017-03-23 Interventions: Behavioral: Gaming CI Therapy Intensive remote (via video game) therapy for upper extremity hemiparesis. |
Recruiting |
Study Name: Armergometry to Improve Mobility in MS Condition: Multiple Sclerosis Date: 2017-03-02 Interventions: Behavioral: arm ergometry home based arm ergometry, at least 4-5 sessions/week for 12 weeks |
Recruiting |
Study Name: Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis Condition: Primary Progressive Multiple Sclerosis Date: 2016-11-08 Interventions: Drug: Dimethyl Fumarate Other |
Recruiting |
Study Name: Hydroxychloroquine in Primary Progressive Multiple Sclerosis Condition: Multiple Sclerosis, Primary Progressive Date: 2016-09-20 Interventions: Drug: Hydroxychloroquine Orally administered Hydroxychloroquine |
Not yet recruiting |
Study Name: Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS) Condition: Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Chronic Pr Date: 2016-07-21 Interventions: Drug: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded w |
Available |
Study Name: Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis Condition: Multiple Sclerosis Date: 2016-06-16 Interventions: Drug: Ocrelizumab Participants will receive 600 mg ocrelizumab as two 300 mg infusions separated by 14 d |
Recruiting |
Study Name: Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) Condition: Relapsing Multiple Sclerorsis Multiple Sclerosis, Primary Progressive Date: 2016-02-18 Interventions: Drug: Ocrelizumab Ocrelizumab |
Completed |
Study Name: Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers Condition: Multiple Sclerosis Date: 2016-01-14 Interventions: Drug: BG00012 (DMF) (Tecfidera®.) Subjects will take DMF 120 mg BID for the first 4 weeks of treatm |
Recruiting |
Study Name: Intrathecal Rituximab in Progressive Multiple Sclerosis Condition: Multiple Sclerosis, Chronic Progressive Nervous System Diseases Date: 2015-09-07 Interventions: Drug: Rituximab IT CSF injecti |